S&P 500   3,247.19 (-2.71%)
DOW   28,171.54 (-2.83%)
QQQ   222.71 (-3.28%)
AAPL   299.35 (-4.38%)
FB   200.95 (-4.39%)
MSFT   172.06 (-3.66%)
GOOGL   1,425.14 (-3.93%)
AMZN   2,008.37 (-4.18%)
CGC   21.06 (-3.75%)
NVDA   278.08 (-5.44%)
BABA   205.39 (-3.39%)
MU   54.68 (-4.05%)
GE   11.94 (-2.53%)
TSLA   853.63 (-5.26%)
AMD   49.56 (-6.98%)
T   38.15 (-1.04%)
ACB   1.59 (-4.79%)
F   7.64 (-3.17%)
PRI   127.64 (-3.54%)
BAC   33.00 (-3.96%)
DIS   132.74 (-4.48%)
GILD   72.82 (+4.46%)
S&P 500   3,247.19 (-2.71%)
DOW   28,171.54 (-2.83%)
QQQ   222.71 (-3.28%)
AAPL   299.35 (-4.38%)
FB   200.95 (-4.39%)
MSFT   172.06 (-3.66%)
GOOGL   1,425.14 (-3.93%)
AMZN   2,008.37 (-4.18%)
CGC   21.06 (-3.75%)
NVDA   278.08 (-5.44%)
BABA   205.39 (-3.39%)
MU   54.68 (-4.05%)
GE   11.94 (-2.53%)
TSLA   853.63 (-5.26%)
AMD   49.56 (-6.98%)
T   38.15 (-1.04%)
ACB   1.59 (-4.79%)
F   7.64 (-3.17%)
PRI   127.64 (-3.54%)
BAC   33.00 (-3.96%)
DIS   132.74 (-4.48%)
GILD   72.82 (+4.46%)
S&P 500   3,247.19 (-2.71%)
DOW   28,171.54 (-2.83%)
QQQ   222.71 (-3.28%)
AAPL   299.35 (-4.38%)
FB   200.95 (-4.39%)
MSFT   172.06 (-3.66%)
GOOGL   1,425.14 (-3.93%)
AMZN   2,008.37 (-4.18%)
CGC   21.06 (-3.75%)
NVDA   278.08 (-5.44%)
BABA   205.39 (-3.39%)
MU   54.68 (-4.05%)
GE   11.94 (-2.53%)
TSLA   853.63 (-5.26%)
AMD   49.56 (-6.98%)
T   38.15 (-1.04%)
ACB   1.59 (-4.79%)
F   7.64 (-3.17%)
PRI   127.64 (-3.54%)
BAC   33.00 (-3.96%)
DIS   132.74 (-4.48%)
GILD   72.82 (+4.46%)
S&P 500   3,247.19 (-2.71%)
DOW   28,171.54 (-2.83%)
QQQ   222.71 (-3.28%)
AAPL   299.35 (-4.38%)
FB   200.95 (-4.39%)
MSFT   172.06 (-3.66%)
GOOGL   1,425.14 (-3.93%)
AMZN   2,008.37 (-4.18%)
CGC   21.06 (-3.75%)
NVDA   278.08 (-5.44%)
BABA   205.39 (-3.39%)
MU   54.68 (-4.05%)
GE   11.94 (-2.53%)
TSLA   853.63 (-5.26%)
AMD   49.56 (-6.98%)
T   38.15 (-1.04%)
ACB   1.59 (-4.79%)
F   7.64 (-3.17%)
PRI   127.64 (-3.54%)
BAC   33.00 (-3.96%)
DIS   132.74 (-4.48%)
GILD   72.82 (+4.46%)
Log in

NASDAQ:CGEN - Compugen Stock Price, Forecast & News

$9.27
-0.73 (-7.30 %)
(As of 02/24/2020 10:49 AM ET)
Today's Range
$9.05
Now: $9.27
$9.66
50-Day Range
$5.81
MA: $7.36
$10.51
52-Week Range
$2.73
Now: $9.27
$10.59
Volume9,942 shs
Average Volume709,087 shs
Market Capitalization$475.46 million
P/E RatioN/A
Dividend YieldN/A
Beta2.72
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGEN
CUSIPN/A
Phone972-3765-8585

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.80 million
Book Value$0.75 per share

Profitability

Net Income$-27,340,000.00

Miscellaneous

Employees89
Market Cap$475.46 million
Next Earnings Date5/18/2020 (Estimated)
OptionableOptionable

Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.


Compugen (NASDAQ:CGEN) Frequently Asked Questions

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) posted its quarterly earnings data on Thursday, February, 20th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. View Compugen's Earnings History.

When is Compugen's next earnings date?

Compugen is scheduled to release their next quarterly earnings announcement on Monday, May 18th 2020. View Earnings Estimates for Compugen.

What price target have analysts set for CGEN?

2 brokers have issued 1 year price objectives for Compugen's stock. Their forecasts range from $9.00 to $13.00. On average, they anticipate Compugen's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price. View Analyst Price Targets for Compugen.

What is the consensus analysts' recommendation for Compugen?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Compugen.

Has Compugen been receiving favorable news coverage?

News stories about CGEN stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Compugen earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Compugen.

Who are some of Compugen's key competitors?

What other stocks do shareholders of Compugen own?

Who are Compugen's key executives?

Compugen's management team includes the folowing people:
  • Dr. Anat Cohen-Dayag, CEO, Pres & Director (Age 52)
  • Mr. Ari Krashin, Chief Financial & Operating Officer (Age 46)
  • Dr. John J. Hunter Ph.D., Chief Scientific Officer (Age 56)
  • Mr. Kirk A. Christoffersen, Sr. VP of Corp. & Bus. Devel. (Age 50)
  • Dr. Zurit Levine, Sr. VP of Technology Innovation (Age 51)

Who are Compugen's major shareholders?

Compugen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (17.50%), Nikko Asset Management Americas Inc. (15.89%), Renaissance Technologies LLC (1.42%), Taylor Frigon Capital Management LLC (1.41%), Rothschild Investment Corp IL (0.67%) and Defender Capital LLC. (0.59%).

Which institutional investors are selling Compugen stock?

CGEN stock was sold by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC, Benjamin F. Edwards & Company Inc., Jane Street Group LLC, UBS Group AG, Phoenix Holdings Ltd. and Raymond James & Associates.

Which institutional investors are buying Compugen stock?

CGEN stock was acquired by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., ARK Investment Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Oxford Asset Management LLP, ProShare Advisors LLC and CWS Financial Advisors LLC.

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $9.27.

How big of a company is Compugen?

Compugen has a market capitalization of $475.46 million and generates $17.80 million in revenue each year. The biotechnology company earns $-27,340,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Compugen employs 89 workers across the globe.View Additional Information About Compugen.

What is Compugen's official website?

The official website for Compugen is http://www.cgen.com/.

How can I contact Compugen?

Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]


MarketBeat Community Rating for Compugen (NASDAQ CGEN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  258 (Thanks for Voting!)
Underperform Votes:  241 (Thanks for Voting!)
Total Votes:  499
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel